Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this ...

Vixarelimab showed rapid, sustained itch reduction and good safety in prurigo nodularis. Learn more about the study and ...

Vixarelimab showed significant symptom relief and disease progression reduction in prurigo nodularis compared with placebo across all doses. A phase 2b trial found vixarelimab rapidly reduced itch and ...

A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor. A review published in Dermatology and ...

Prurigo nodularis, a chronic debilitating inflammatory skin disease that causes extreme quality of life disruptions, affects approximately 75,000 adults in the United States, who are most in need of ...

The first and only treatment for the disabling skin condition prurigo nodularis has been approved by the Food and Drug Administration in a development a D.C. dermatologist calls “huge.” Prurigo ...

A new study published in The Journal of Dermatology showed that prurigo nodularis is associated with a considerably higher ...

Please provide your email address to receive an email when new articles are posted on . Patients with prurigo nodularis experience significant impairment to their quality of life and individual ...

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved Acceptance marks another important step in advancing Dupixent for a broad range ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA has ...

Prurigo nodularis is a disabling chronic skin condition characterized by severely itchy, crusty, firm papules and nodules that often occur on the arms and legs, but can appear diffusely on the body.

The prurigo nodularis treatment landscape has been evolving in recent years, with increasing attention from the pharmaceutical industry due to the chronic and debilitating nature of the condition.